395 related articles for article (PubMed ID: 18265633)
21. Expression of retinoblastoma and p53 pathway-related proteins in resectable invasive ductal carcinoma of the pancreas: potential cooperative effects on clinical outcome.
Hashimoto K; Nio Y; Koike M; Itakura M; Yano S; Higami T; Maruyama R
Anticancer Res; 2005; 25(2B):1361-8. PubMed ID: 15865092
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological features of pancreatic intraepithelial neoplasias and their relationship to intraductal papillary-mucinous tumors.
Takaori K; Kobashi Y; Matsusue S; Matsui K; Yamamoto T
J Hepatobiliary Pancreat Surg; 2003; 10(2):125-36. PubMed ID: 14505145
[TBL] [Abstract][Full Text] [Related]
23. CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer.
Ikenaga N; Ohuchida K; Mizumoto K; Cui L; Kayashima T; Morimatsu K; Moriyama T; Nakata K; Fujita H; Tanaka M
Gastroenterology; 2010 Sep; 139(3):1041-51, 1051.e1-8. PubMed ID: 20685603
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
Yamasawa K; Nio Y; Dong M; Yamaguchi K; Itakura M
Clin Cancer Res; 2002 Aug; 8(8):2563-9. PubMed ID: 12171884
[TBL] [Abstract][Full Text] [Related]
25. Comparison between mucinous cystic neoplasm and intraductal papillary mucinous neoplasm of the branch duct type of the pancreas with respect to expression of CD10 and cytokeratin 20.
Nishigami T; Onodera M; Torii I; Sato A; Tao LH; Kushima R; Kakuno A; Kishimoto M; Katsuyama E; Fujimori T; Hirano H; Satake M; Kuroda N; Nishiguchi S; Fujimoto J; Tsujimura T
Pancreas; 2009 Jul; 38(5):558-64. PubMed ID: 19287335
[TBL] [Abstract][Full Text] [Related]
26. Expression analysis of PMP22/Gas3 in premalignant and malignant pancreatic lesions.
Li J; Kleeff J; Esposito I; Kayed H; Felix K; Giese T; Büchler MW; Friess H
J Histochem Cytochem; 2005 Jul; 53(7):885-93. PubMed ID: 15995147
[TBL] [Abstract][Full Text] [Related]
27. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance.
Schleger C; Verbeke C; Hildenbrand R; Zentgraf H; Bleyl U
Mod Pathol; 2002 Apr; 15(4):462-9. PubMed ID: 11950922
[TBL] [Abstract][Full Text] [Related]
28. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas.
Uehara H; Nakaizumi A; Ishikawa O; Iishi H; Tatsumi K; Takakura R; Ishida T; Takano Y; Tanaka S; Takenaka A
Gut; 2008 Nov; 57(11):1561-5. PubMed ID: 18477671
[TBL] [Abstract][Full Text] [Related]
29. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Liang JJ; Wang H; Rashid A; Tan TH; Hwang RF; Hamilton SR; Abbruzzese JL; Evans DB; Wang H
Clin Cancer Res; 2008 Nov; 14(21):7043-9. PubMed ID: 18981001
[TBL] [Abstract][Full Text] [Related]
30. Different patterns of p16INK4A and p53 protein expressions in intraductal papillary-mucinous neoplasms and pancreatic intraepithelial neoplasia.
Abe K; Suda K; Arakawa A; Yamasaki S; Sonoue H; Mitani K; Nobukawa B
Pancreas; 2007 Jan; 34(1):85-91. PubMed ID: 17198188
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas.
Shimamura T; Sakamoto M; Ino Y; Shimada K; Kosuge T; Sato Y; Tanaka K; Sekihara H; Hirohashi S
Clin Cancer Res; 2002 Aug; 8(8):2570-5. PubMed ID: 12171885
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of frozen section analysis during resection of intraductal papillary mucinous neoplasm: should a positive pancreatic margin for adenoma or borderline lesion be resected additionally?
Nara S; Shimada K; Sakamoto Y; Esaki M; Kosuge T; Hiraoka N
J Am Coll Surg; 2009 Nov; 209(5):614-21. PubMed ID: 19854402
[TBL] [Abstract][Full Text] [Related]
33. Prognosis of invasive intraductal papillary mucinous neoplasm.
Longnecker DS; Klöppel G
Pancreas; 2008 Oct; 37(3):333; author reply 333-4. PubMed ID: 18815559
[No Abstract] [Full Text] [Related]
34. Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis.
Dittert DD; Kielisch C; Alldinger I; Zietz C; Meyer W; Dobrowolski F; Saeger HD; Baretton GB
Hum Pathol; 2008 Jul; 39(7):1002-10. PubMed ID: 18495213
[TBL] [Abstract][Full Text] [Related]
35. Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors.
Hirono S; Tani M; Kawai M; Ina S; Nishioka R; Miyazawa M; Fujita Y; Uchiyama K; Yamaue H
Arch Surg; 2009 Apr; 144(4):345-9; discussion 349-50. PubMed ID: 19380648
[TBL] [Abstract][Full Text] [Related]
36. Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas.
Qi T; Han J; Cui Y; Zong M; Liu X; Zhu B
J Clin Pathol; 2008 Jan; 61(1):49-58. PubMed ID: 17412869
[TBL] [Abstract][Full Text] [Related]
37. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma.
Ben QW; Wang JC; Liu J; Zhu Y; Yuan F; Yao WY; Yuan YZ
Ann Surg Oncol; 2010 Aug; 17(8):2213-21. PubMed ID: 20162456
[TBL] [Abstract][Full Text] [Related]
38. Mucinous cystic neoplasms of the pancreas: pathology and molecular genetics.
Fukushima N; Fukayama M
J Hepatobiliary Pancreat Surg; 2007; 14(3):238-42. PubMed ID: 17520198
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological significance of cell cycle regulatory factors and differentiation-related factors in pancreatic neoplasms.
Kamio Y; Maeda K; Moriya T; Takasu N; Takeshita A; Hirai I; Kimura W; Yamakawa M
Pancreas; 2010 Apr; 39(3):345-52. PubMed ID: 20335778
[TBL] [Abstract][Full Text] [Related]
40. Morphometric microvascular characteristics in the prognosis of pancreatic and ampullary carcinoma.
Giannopoulos G; Kavantzas N; Parasi A; Tiniakos D; Peros G; Tzanakis N; Patsouris E; Pavlakis K
Pancreas; 2007 Jul; 35(1):47-52. PubMed ID: 17575545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
